CN110691596A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN110691596A
CN110691596A CN201880035549.0A CN201880035549A CN110691596A CN 110691596 A CN110691596 A CN 110691596A CN 201880035549 A CN201880035549 A CN 201880035549A CN 110691596 A CN110691596 A CN 110691596A
Authority
CN
China
Prior art keywords
dihydrotetrabenazine
pharmaceutically acceptable
subject
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880035549.0A
Other languages
English (en)
Chinese (zh)
Inventor
安德鲁·约翰·达菲尔德
阿南特·潘迪亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adeputio Pharmaceutical Co Ltd
Original Assignee
Adeputio Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1705305.9A external-priority patent/GB201705305D0/en
Priority claimed from GBGB1705304.2A external-priority patent/GB201705304D0/en
Priority claimed from GBGB1705306.7A external-priority patent/GB201705306D0/en
Application filed by Adeputio Pharmaceutical Co Ltd filed Critical Adeputio Pharmaceutical Co Ltd
Publication of CN110691596A publication Critical patent/CN110691596A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880035549.0A 2017-04-01 2018-03-29 药物组合物 Pending CN110691596A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GBGB1705305.9A GB201705305D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GB1705305.9 2017-04-01
GBGB1705304.2A GB201705304D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GB1705304.2 2017-04-01
GB1705306.7 2017-04-01
GBGB1705306.7A GB201705306D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
US201762515930P 2017-06-06 2017-06-06
US201762515940P 2017-06-06 2017-06-06
US201762515935P 2017-06-06 2017-06-06
US62/515,935 2017-06-06
US62/515,930 2017-06-06
US62/515,940 2017-06-06
PCT/EP2018/058088 WO2018178243A2 (fr) 2017-04-01 2018-03-29 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
CN110691596A true CN110691596A (zh) 2020-01-14

Family

ID=63674294

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880035549.0A Pending CN110691596A (zh) 2017-04-01 2018-03-29 药物组合物

Country Status (7)

Country Link
EP (1) EP3606530A2 (fr)
JP (2) JP7250692B2 (fr)
CN (1) CN110691596A (fr)
AU (2) AU2018241940B2 (fr)
CA (1) CA3057548A1 (fr)
RU (2) RU2022104034A (fr)
WO (1) WO2018178243A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769826A (zh) 2017-01-27 2020-02-07 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
MA50175A (fr) 2017-09-21 2021-04-21 Neurocrine Biosciences Inc Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
CN111836543A (zh) 2017-10-10 2020-10-27 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
AU2019322863A1 (en) 2018-08-15 2021-03-11 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053067A2 (fr) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Traitement de l'hypercinesie associant l'amantadine a un compose tetrabenazinique
CN1980924A (zh) * 2004-02-11 2007-06-13 剑桥实验室（爱尔兰）有限公司 二氢丁苯那嗪类及包含它们的药用组合物
US20080167337A1 (en) * 2006-11-08 2008-07-10 Gano Kyle W Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH341161A (de) * 1956-02-08 1959-09-30 Hoffmann La Roche Verfahren zur Herstellung von substituierten 2-Hydroxy-benzo [ a ] chinolizinen
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011153157A2 (fr) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Inhibiteurs benzoquinolone de vmat2
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
CN116768882A (zh) * 2012-09-18 2023-09-19 奥斯拜客斯制药有限公司 化合物、及其药物组合物及治疗方法
EP3102190A4 (fr) * 2014-02-07 2017-09-06 Auspex Pharmaceuticals, Inc. Nouvelles formulations pharmaceutiques
MX2016014429A (es) * 2014-05-06 2017-04-06 Neurocrine Biosciences Inc Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1980924A (zh) * 2004-02-11 2007-06-13 剑桥实验室（爱尔兰）有限公司 二氢丁苯那嗪类及包含它们的药用组合物
WO2006053067A2 (fr) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Traitement de l'hypercinesie associant l'amantadine a un compose tetrabenazinique
US20080167337A1 (en) * 2006-11-08 2008-07-10 Gano Kyle W Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACK J. CHEN ET AL: "Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature", 《CLINICAL THERAPEUTICS》 *
ZHANGYU YAO ET AL: "Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
CA3057548A1 (fr) 2018-10-04
JP2020512987A (ja) 2020-04-30
WO2018178243A2 (fr) 2018-10-04
AU2023274089A1 (en) 2023-12-14
EP3606530A2 (fr) 2020-02-12
RU2019134416A (ru) 2021-05-04
WO2018178243A3 (fr) 2018-12-13
RU2022104034A (ru) 2022-03-05
JP7250692B2 (ja) 2023-04-03
AU2018241940A1 (en) 2019-10-03
RU2768738C2 (ru) 2022-03-24
AU2018241940B2 (en) 2023-09-28
JP2023029975A (ja) 2023-03-07
RU2019134416A3 (fr) 2021-08-18

Similar Documents

Publication Publication Date Title
AU2018242134B2 (en) (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
CN110691596A (zh) 药物组合物
US11844794B2 (en) Pharmaceutical compositions
US20220211678A1 (en) Uses of (+)-a-dihydrotetrabenazine in methods of treating movement disorder
US20180280360A1 (en) Pharmaceutical compositions
US11844786B2 (en) Uses of combinations (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine in methods of treating movement disorder
US10668052B2 (en) Combinations of isomers of dihydrotetrabenazine
EP3860599B1 (fr) Régime posologique de (+)-alpha-dihydrotétrabénazine destiné au traitement de troubles du mouvement
RU2783865C2 (ru) Фармацевтические композиции

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination